Improved curve fits to summary survival data: application to economic evaluation of health technologies

Martin Hoyle, William Henley

Research output: Contribution to journalArticlepeer-review

97 Citations (Scopus)
11 Downloads (Pure)

Abstract

Background: Mean costs and quality-adjusted-life-years are central to the cost-effectiveness of health technologies. They are often calculated from time to event curves such as for overall survival and progression-free survival. Ideally, estimates should be obtained from fitting an appropriate parametric model to individual patient data. However, such data are usually not available to independent researchers. Instead, it is common to fit curves to summary Kaplan-Meier graphs, either by regression or by least squares. Here, a more accurate method of fitting survival curves to summary survival data is described.

Methods: First, the underlying individual patient data are estimated from the numbers of patients at risk (or other published information) and from the Kaplan-Meier graph. The survival curve can then be fit by maximum likelihood estimation or other suitable approach applied to the estimated individual patient data. The accuracy of the proposed method was compared against that of the regression and least squares methods and the use of the actual individual patient data by simulating the survival of patients in many thousands of trials. The cost-effectiveness of sunitinib versus interferon-alpha for metastatic renal cell carcinoma, as recently calculated for NICE in the UK, is reassessed under several methods, including the proposed method.

Results: Simulation shows that the proposed method gives more accurate curve fits than the traditional methods under realistic scenarios. Furthermore, the proposed method achieves similar bias and mean square error when estimating the mean survival time to that achieved by analysis of the complete underlying individual patient data. The proposed method also naturally yields estimates of the uncertainty in curve fits, which are not available using the traditional methods. The cost-effectiveness of sunitinib versus interferon-alpha is substantially altered when the proposed method is used.

Conclusions: The method is recommended for cost-effectiveness analysis when only summary survival data are available. An easy-to-use Excel spreadsheet to implement the method is provided.
Original languageEnglish
Article number139
Number of pages14
JournalBMC Medical Research Methodology
Volume11
DOIs
Publication statusPublished - 2011
Externally publishedYes

Bibliographical note

Copyright 2011 Hoyle and Henley; licensee BioMed Central Ltd. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.

Keywords

  • Renal Cell Carcinoma
  • Sunitinib
  • Survival Probability
  • Weibull Distribution
  • Individual Patient Data

Fingerprint Dive into the research topics of 'Improved curve fits to summary survival data: application to economic evaluation of health technologies'. Together they form a unique fingerprint.

Cite this